secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2023-04-20T23:59:59+00:00
Accession:  0001213900-23-031332
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio amends license agreements, removes clinical milestones; reports XPro1595 pre-clinical data in TBI-AD model
--------------------------------------------------------------------------------

- Amended INKmune license with Immune Ventures: removed all due diligence including clinical trial and NDA filing requirements.
- Amended PITT license: replaced milestones with Phase II first patient dose by June 2026, marketing authorization by June 2031.
- Pre-clinical study shows XPro1595 prevents amyloid pathology in mouse model of TBI-induced Alzheimer's disease.
- Data presented at AD/PD 2023 conference in Gothenburg, Sweden on April 1, 2023.
- XPro1595 neutralizes soluble TNF without affecting transmembrane TNF; currently in clinical trials for neurologic disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390023031332/0001213900-23-031332-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390023031332/ea177097-8k_inmunebio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-031332

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer